Merge pull request 'vida: research session 2026-03-18' (#1194) from vida/research-2026-03-18 into main

agents/vida/musings/research-2026-03-18.md

@@ -0,0 +1,147 @@
+---
+status: seed
+type: musing
+stage: developing
+created: 2026-03-18
+last_updated: 2026-03-18
+tags: [behavioral-health, community-health, social-prescribing, sdoh, food-as-medicine, research-session]
+---
+
+# Research Session: Behavioral Health Infrastructure — What Actually Works at Scale?
+
+## Research Question
+
+**What community-based and behavioral health interventions have the strongest evidence for scalable, cost-effective impact on non-clinical health determinants — and what implementation mechanisms distinguish programs that scale from those that stall?**
+
+## Why This Question
+
+**Priority level: Frontier Gap 1 (highest impact)**
+
+Three sessions of GLP-1 research have deepened the economic understanding but the remaining threads (BALANCE launch, RCT replication) need time to materialize. The frontier audit ranks Behavioral Health Infrastructure as Gap 1 because:
+
+1. **Belief 2 depends on it.** "80-90% of health outcomes are non-clinical" is foundational — but the KB has almost no evidence about WHAT interventions change those outcomes. The claim that non-clinical factors dominate is well-grounded; the claim that we can DO anything about them at scale is ungrounded.
+
+2. **Research directive alignment.** Cory flagged "Health equity and SDOH intervention economics" as a specific priority area.
+
+3. **Active inference principle.** Three sessions on GLP-1 and clinical AI have been confirmatory (deepening existing understanding). This question pursues SURPRISE — I genuinely don't know what the evidence says about community health worker programs, social prescribing, or food-as-medicine at scale.
+
+4. **Cross-domain potential.** Behavioral infrastructure connects to Clay (narrative/meaning as health intervention), Rio (funding mechanisms for non-clinical health), and Leo (civilizational capacity through population health).
+
+**What would change my mind:**
+- If community health interventions show strong efficacy in RCTs but consistently fail to scale → the problem is implementation infrastructure, not intervention design
+- If social prescribing (UK model) shows measurable population-level outcomes → international evidence strengthens the comparative health gap (Frontier Gap 2)
+- If food-as-medicine programs show ROI under Medicaid managed care → direct connection to VBC economics from previous sessions
+- If the evidence is weaker than I expect → Belief 2 needs a "challenges considered" update acknowledging the intervention gap
+
+## What I Found
+
+### The Core Discovery: A Three-Way Taxonomy of Non-Clinical Intervention Failure Modes
+
+The four tracks revealed that non-clinical health interventions fail for THREE distinct reasons, and conflating them leads to bad policy:
+
+**Type 1: Evidence-rich, implementation-poor (CHW programs)**
+- 39 US RCTs with consistent positive outcomes
+- IMPaCT: $2.47 ROI per Medicaid dollar within one fiscal year, 65% reduction in hospital days
+- BUT: only 20 states have Medicaid SPAs after 17 years since Minnesota's 2008 approval
+- Barrier: billing infrastructure, CBO contracting capacity, transportation costs
+- The problem is NOT "does it work?" but "can the payment system pay for it?"
+
+**Type 2: Implementation-rich, evidence-poor (UK social prescribing)**
+- 1.3 million patients referred in 2023 alone, 3,300 link workers, exceeding NHS targets by 52%
+- BUT: 15 of 17 utilization studies are uncontrolled before-and-after designs
+- 38% attrition rate, no standardized outcome measures
+- Financial ROI: only 0.11-0.43 per £1 (social value higher at SROI £1.17-£7.08)
+- The problem is NOT "can we implement it?" but "do we know if it works?"
+
+**Type 3: Theory-rich, RCT-poor (food-as-medicine)**
+- Tufts simulation: 10.8M hospitalizations prevented, $111B savings over 5 years
+- BUT: JAMA Internal Medicine 2024 RCT — intensive food program (10 meals/week + education + coaching) showed NO significant glycemic improvement vs. control
+- AHA systematic review of 14 RCTs: "impact on clinical outcomes was inconsistent and often failed to reach statistical significance"
+- Geisinger Fresh Food Farmacy: dramatic results (HbA1c 9.6→7.5) but n=37, uncontrolled, self-selected
+- The problem: observational association (food insecurity predicts disease) ≠ causal mechanism (providing food improves health)
+
+**The exception: Behavioral economics defaults**
+- CHIBE statin default: 71% → 92% prescribing compliance, REDUCED disparities
+- Works through SYSTEM modification (EHR defaults) not patient behavior change
+- Near-zero marginal cost per patient, scales instantly
+- The mechanism: change the environment, not the person
+
+### Track-by-Track Details
+
+#### Track 1: Community Health Workers — The Strongest Evidence, The Weakest Infrastructure
+
+**Scoping review (Gimm et al., 2025):** 39 US RCTs from 2000-2023. All 13 RCTs examining specific health outcomes showed improved outcomes. Consistent evidence across settings. But most research is in healthcare systems — almost none in payer or public health agency settings.
+
+**IMPaCT (Penn Medicine):** The gold standard. RCT-validated: $2.47 ROI per Medicaid dollar within the fiscal year. 65% reduction in total hospital days. Doubled patient satisfaction with primary care. Improved chronic disease control and mental health. Annual savings: $1.4M for Medicaid enrollees.
+
+**State policy landscape (NASHP):** 20 states have SPAs for CHW reimbursement. 15 have Section 1115 waivers. 7 states established dedicated CHW offices. BUT: billing code uptake is slow, CBOs lack contracting infrastructure, transportation is largest overhead and Medicaid doesn't cover it. Community care hubs emerging as coordination layer. COVID funding ending creates immediate gaps.
+
+Key insight: CHW programs generate same-year ROI — they don't require the multi-year time horizon that blocks other prevention investments. The barrier is NOT the economics but the administrative infrastructure connecting proven programs to payment.
+
+#### Track 2: Social Prescribing — Scale Without Evidence
+
+**Lancet Public Health (2025):** England's national rollout analyzed across 1.2M patients, 1,736 practices. 9.4M GP consultations involved social prescribing codes. 1.3M patients referred in 2023 alone. Equity improved: deprived area representation up from 23% to 42%. Service refusal down from 22% to 12%.
+
+**Healthcare utilization claims:** 28% GP reduction, 24% A&E reduction on average. But: huge variation (GP: 2-70%), and one study found workload was NOT reduced overall despite patient-level improvements.
+
+**Frontiers systematic review (2026):** 18 studies (only 5 RCTs). SROI positive (£1.17-£7.08 per £1). But financial ROI only 0.11-0.43 per £1. "Robust economic evidence on social prescribing remains limited." Standard health economic methods "rarely applied." No standardized outcomes.
+
+Key insight: Social prescribing creates real social value but may not save healthcare money. The SROI/financial ROI gap means the VALUE exists but the PAYER doesn't capture it. This is a structural misalignment problem — social value accrues to individuals and communities while costs sit with the NHS.
+
+#### Track 3: Food-as-Medicine — The Causal Inference Gap
+
+**Tufts/Health Affairs simulation (2025):** 14M+ eligible Americans. $23B first-year savings. 10.8M hospitalizations prevented over 5 years. Net cost-saving in 49 of 50 states. Eligible population averages $30,900/year in healthcare costs.
+
+**JAMA Internal Medicine RCT (2024):** Intensive food-as-medicine for diabetes + food insecurity. 10 meals/week + education + nurse evaluations + health coaching for 1 year. Result: HbA1c improvement NOT significantly different from control (P=.57). No significant differences in hospitalizations, ED use, or claims.
+
+**AHA Scientific Statement (Circulation, 2025):** 14 US RCTs reviewed. Food Is Medicine "often positively influences diet quality and food security" but "impact on clinical outcomes was inconsistent and often failed to reach statistical significance."
+
+**Geisinger Fresh Food Farmacy:** HbA1c 9.6→7.5 (2.1 points vs. 0.5-1.2 from medication). Costs down 80%. BUT: n=37, uncontrolled, self-selected.
+
+Key insight: The simulation-to-RCT gap is the most important methodological finding. Simulation models extrapolate from observational associations (food insecurity → disease). But the JAMA RCT tests the causal intervention (provide food → improve health) and finds nothing. The observational association may reflect confounding (poverty drives both food insecurity AND poor health) rather than a causal pathway that providing food alone can fix.
+
+#### Track 4: Behavioral Economics — System Modification Beats Patient Modification
+
+**CHIBE statin default (JAMA Internal Medicine):** Switching EHR default to 90-day supply with 3 refills → 71% to 92% compliance. Also REDUCED racial and socioeconomic disparities. The mechanism: defaults change clinician behavior without requiring patient engagement.
+
+**Healthcare appointments as commitment devices:** Ordinary appointments more than double testing rates. Effects concentrated among those with self-control problems. Appointments substitute for "hard" commitment devices.
+
+**Other CHIBE results:** Opioid guidelines adherence 57.2% → 71.8% via peer comparison. Game-based intervention +1,700 steps/day. Colonoscopy show rates +6 percentage points with reduced staff workload.
+
+Key insight: Behavioral economics interventions that modify the SYSTEM (EHR defaults, appointment scheduling, choice architecture) produce larger, more equitable effects than interventions that try to modify PATIENT behavior (education, motivation, coaching). This has profound implications for where to invest: configure the environment, don't try to change the person.
+
+### Synthesis: What This Means for Belief 2
+
+Belief 2 ("80-90% of health outcomes are non-clinical") is CORRECT about the diagnosis but the KB has been SILENT on the prescription. This session fills that gap — and the prescription is harder than I expected.
+
+**The good news:** CHW programs and behavioral defaults have strong RCT evidence for improving non-clinical health outcomes AND generating healthcare cost savings.
+
+**The bad news:** Two of the highest-profile non-clinical interventions — social prescribing and food-as-medicine — have weak-to-null RCT evidence for clinical outcomes despite massive investment and implementation.
+
+**The implication:** Non-clinical health interventions are NOT a homogeneous category. Some work through system modification (defaults, CHW integration) and generate measurable savings. Others work through person-level behavior change (food provision, social activities) and may produce social value without clinical benefit. The KB needs to distinguish between these mechanisms, not treat "non-clinical intervention" as a single category.
+
+## Belief Updates
+
+**Belief 2 (non-clinical determinants):** COMPLICATED. The 80-90% figure remains well-supported — non-clinical factors dominate health outcomes. But the INTERVENABILITY of those factors is much weaker than I assumed. Food-as-medicine RCTs show null clinical results despite intensive programs. The "challenges considered" section needs updating: "Identifying the non-clinical determinants that drive health outcomes does not mean that providing the missing determinant (food, social connection, housing) automatically improves outcomes. The causal pathway may run through deeper mechanisms (poverty, meaning, community structure) that determinant-specific interventions don't address."
+
+**Existing SDOH claim needs scope qualification:** "SDOH interventions show strong ROI but adoption stalls" is partially wrong. CHW programs show strong ROI. But food-as-medicine RCTs don't show clinical benefit. And social prescribing shows social value but not financial ROI. The claim needs to distinguish intervention types.
+
+## Follow-up Directions
+
+### NEXT: (continue next session)
+- **CHW scaling mechanisms:** What distinguishes the 20 states with SPAs from the 30 without? What is the community care hub model and does it solve the CBO contracting gap? Key question: can CHW billing infrastructure scale faster than VBC payment infrastructure?
+- **Food-as-medicine causal pathway:** Why does the Geisinger pilot (n=37) show dramatic results while the JAMA RCT (larger, controlled) shows nothing? Is it self-selection? Is it the integrated care model (Geisinger is a health system, not just a food program)? Key question: does food-as-medicine work only when embedded in comprehensive care systems?
+- **Default effects in non-prescribing domains:** CHIBE has proven defaults work for prescribing. Do similar mechanisms work for social determinant screening, referral follow-through, or behavioral health? Key question: can EHR defaults create the "simple enabling rules" for SDOH interventions?
+
+### COMPLETED: (threads finished)
+- **Behavioral health infrastructure evidence landscape:** Four intervention types assessed with evidence quality mapped. Ready for extraction.
+- **International social prescribing evidence:** UK Lancet study archived. First international health system data in Vida's KB.
+
+### DEAD ENDS: (don't re-run)
+- **Tweet feeds:** Fifth session, still empty. Confirmed dead end.
+
+### ROUTE: (for other agents)
+- **Behavioral economics default effects → Rio:** Default effects and commitment devices are mechanism design applied to health. Rio should evaluate whether futarchy or prediction market mechanisms could improve health intervention selection. The CHIBE evidence shows that changing choice architecture works better than educating individuals — this is directly relevant to Rio's governance mechanism work.
+- **Social value vs. financial value divergence → Leo:** Social prescribing produces SROI £1.17-£7.08 but financial ROI only 0.11-0.43. This is a civilizational infrastructure problem: the value is real but accrues to individuals/communities while costs sit with healthcare payers. Leo's cross-domain synthesis should address how societies value and fund interventions that produce social returns without financial returns.
+- **Food-as-medicine causal inference gap → Theseus:** The simulation-vs-RCT gap in food-as-medicine is an epistemological problem. Models trained on observational associations produce confident predictions that RCTs falsify. This parallels Theseus's work on AI benchmark-vs-deployment gaps — models that score well on benchmarks but fail in practice.
+

agents/vida/research-journal.md

@@ -49,3 +49,20 @@ On clinical AI: a two-track story is emerging. Documentation AI (Abridge territo
 
 **Sources archived:** 9 across four tracks (GLP-1 digital adherence, BALANCE design, Epic AI Charting disruption, Abridge/OpenEvidence growth)
 **Extraction candidates:** 5-6 claims: GLP-1 as behavioral catalyst (not standalone), BALANCE dual-payment mechanism, Epic platform commoditization of documentation AI, Abridge platform pivot under pressure, OpenEvidence scale without outcomes data, ambient AI burnout mechanism (cognitive load, not just time)
+
+## Session 2026-03-18 — Behavioral Health Infrastructure: What Actually Works at Scale?
+
+**Question:** What community-based and behavioral health interventions have the strongest evidence for scalable, cost-effective impact on non-clinical health determinants — and what implementation mechanisms distinguish programs that scale from those that stall?
+
+**Key finding:** Non-clinical health interventions are NOT a homogeneous category. They fail for three distinct reasons: (1) CHW programs have strong RCT evidence (39 US trials, $2.47 Medicaid ROI) but can't scale because only 20 states have reimbursement infrastructure; (2) UK social prescribing scaled to 1.3M referrals/year but has weak evidence (15/17 studies uncontrolled, financial ROI only 0.11-0.43 per £1); (3) food-as-medicine has massive simulation projections ($111B savings) but the JAMA Internal Medicine RCT showed NO significant glycemic improvement vs. control. The exception: EHR default effects (CHIBE) produce large effects (71%→92% statin compliance), reduce disparities, and scale at near-zero marginal cost by modifying the SYSTEM rather than the PATIENT.
+
+**Pattern update:** Four sessions now reveal a consistent meta-pattern: the gap between what SHOULD work in theory and what DOES work in practice. Sessions 1-3 showed this for VBC (payment alignment doesn't automatically create prevention incentives). Session 4 shows the same gap for SDOH interventions (identifying non-clinical determinants doesn't automatically mean fixing them improves outcomes). The food-as-medicine RCT null result is particularly important: observational association (food insecurity → disease) ≠ causal mechanism (providing food → health improvement). The confounding factor may be poverty itself, not any single determinant.
+
+**Cross-session pattern deepening:** The interventions that WORK (CHW programs, EHR defaults) modify the system or provide human connection. The interventions that DON'T reliably work in RCTs (food provision, social activities) provide resources without addressing underlying mechanisms. This suggests that the 80-90% non-clinical determinant claim is about the DIAGNOSIS (what predicts poor health) not the PRESCRIPTION (what fixes it). The prescription may require fundamentally different approaches — system architecture changes (defaults, workflow integration) and human relational models (CHWs, care coordination) — rather than resource provision (food, social activities).
+
+**Confidence shift:**
+- Belief 2 (non-clinical determinants): **COMPLICATED** — the 80-90% figure stands as diagnosis but the intervenability of those determinants is much weaker than assumed. Food-as-medicine RCTs show null clinical results. The "challenges considered" section needs updating.
+- Existing SDOH claim: **needs scope qualification** — "strong ROI" applies to CHW programs but NOT to food-as-medicine or social prescribing (financial ROI). Should distinguish intervention types.
+
+**Sources archived:** 6 across four tracks (CHW RCT review, NASHP state policy, Lancet social prescribing, Tufts/JAMA food-as-medicine, CHIBE behavioral economics, Frontiers social prescribing economics)
+**Extraction candidates:** 6-8 claims: CHW programs as most RCT-validated non-clinical intervention, CHW reimbursement boundary parallels VBC payment stall, social prescribing scale-without-evidence paradox, food-as-medicine simulation-vs-RCT causal inference gap, EHR defaults as highest-leverage behavioral intervention, non-clinical interventions taxonomy (system modification vs. resource provision)

inbox/archive/2025-01-01-chibe-behavioral-economics-health-nudges-defaults-rct.md

@@ -0,0 +1,60 @@
+---
+type: source
+title: "Penn CHIBE Behavioral Economics Health Interventions: Default Nudges Raise Statin Prescribing from 71% to 92% and Reduce Health Disparities"
+author: "Center for Health Incentives and Behavioral Economics (CHIBE), University of Pennsylvania"
+url: https://chibe.upenn.edu/chibe-annual-report-2024-2025/
+date: 2025-01-01
+domain: health
+secondary_domains: []
+format: report
+status: unprocessed
+priority: medium
+triage_tag: claim
+tags: [behavioral-economics, nudges, default-effects, medication-adherence, health-disparities, EHR]
+flagged_for_rio: ["Behavioral economics mechanisms (commitment devices, default effects) are directly relevant to mechanism design in health contexts"]
+---
+
+## Content
+
+CHIBE 2024-2025 annual report documenting RCT-validated behavioral economics interventions in health.
+
+Key RCT results:
+
+1. **Statin default prescription length (JAMA Internal Medicine):**
+   - Intervention: switched EHR default to 90-day supply with 3 refills (opt-out)
+   - Result: prescriptions at 90-day supply increased from 71% to 92%
+   - Bonus: racial and socioeconomic disparities in prescription length were REDUCED
+   - Mechanism: default effect (opt-out vs. opt-in changes clinician behavior)
+
+2. **Opioid prescribing guidelines adherence:**
+   - Peer comparison + patient-reported outcomes feedback
+   - Adherence increased from 57.2% to 71.8%
+
+3. **Physical activity (Alzheimer's risk):**
+   - Game-based intervention with support partner
+   - Increased step counts by 1,700 steps/day (equivalent to 70+ miles over intervention)
+
+4. **Healthcare appointments as commitment devices (PMC, 2025):**
+   - Ordinary appointments act as effective substitutes for hard commitment devices
+   - More than double testing rates
+   - Effects concentrated among those with self-control problems
+
+5. **Colonoscopy show rates:**
+   - Scaled intervention improved show rates by 6 percentage points
+   - Simultaneously reduced staff workload
+
+Additional context:
+- $49M total CHIBE grant activity in FY2025
+- Penn Medicine Healthy Heart trial: 2,000 patients in West/Southwest Philadelphia and Lancaster County (2024-2025) testing behavioral nudges for blood pressure and cholesterol management from home
+- Penn Medicine now funding scaled implementation of automated pharmacy referral program that increased statin prescribing
+
+## Agent Notes
+**Triage:** [CLAIM] — Default effects in EHR systems are the highest-leverage behavioral economics intervention in healthcare: minimal cost, large effect sizes, and they REDUCE rather than widen health disparities
+**Why this matters:** Default effects are the strongest evidence for behavioral economics in health because they work through the SYSTEM (EHR configuration) not through the PATIENT (motivation, education). This means they can scale without per-patient cost — configure the EHR once, change behavior for every patient. And the disparity-reducing effect is remarkable: the default helps the least-advantaged patients most.
+**What surprised me:** The disparity reduction. Most health interventions that work for the general population work LESS well for disadvantaged populations. Default effects work BETTER for disadvantaged populations because they remove the cognitive/administrative burden that disproportionately affects vulnerable patients.
+**KB connections:** [[medical care explains only 10-20 percent of health outcomes...]], [[SDOH interventions show strong ROI but adoption stalls...]], [[healthcare is a complex adaptive system requiring simple enabling rules...]]
+**Extraction hints:** Claim candidates: (1) "EHR default effects are the highest-leverage behavioral health intervention because they scale at near-zero marginal cost, produce large effect sizes (71% to 92%), and reduce rather than widen health disparities"; (2) "Behavioral economics interventions in healthcare work best when they modify the SYSTEM environment (defaults, prompts, architecture) rather than the PATIENT behavior (education, motivation, adherence)"
+
+## Curator Notes
+PRIMARY CONNECTION: healthcare is a complex adaptive system requiring simple enabling rules not complicated management because standardized processes erode the clinical autonomy needed for value creation
+WHY ARCHIVED: Default effects are the "simple enabling rules" the complex adaptive system claim describes. The CHIBE evidence makes this concrete: change the EHR default → change prescribing behavior → reduce disparities. This is the behavioral economics bridge between the KB's structural claims and operational interventions.

inbox/archive/2025-01-01-gimm-hoffman-chw-rct-scoping-review.md

@@ -0,0 +1,45 @@
+---
+type: source
+title: "A Scoping Review of RCT Studies on Community Health Worker Effectiveness"
+author: "Gilbert Gimm, Carolyn Hoffman, Leila Elahi, Len M. Nichols"
+url: https://journals.sagepub.com/doi/10.1177/19427891251384659
+date: 2025-01-01
+domain: health
+secondary_domains: []
+format: paper
+status: unprocessed
+priority: high
+triage_tag: claim
+tags: [community-health-workers, RCT, evidence-review, SDOH, behavioral-health-infrastructure]
+---
+
+## Content
+
+Scoping review of 39 RCT studies on community health worker (CHW) interventions in the US, published between 2000-2023. All 13 RCT studies examining specific health outcomes showed modest to strong evidence of improved clinical, education, or utilization outcomes in the treatment group relative to the control group.
+
+Key findings:
+- 39 RCTs identified in US settings
+- Most rigorous trials occurred in health care systems and safety-net providers/community health centers
+- Limited research in public health agencies or insurance organizations
+- Consistent evidence of improved outcomes across CHW interventions
+- Gap: many CHW intervention studies do not clearly specify organizational setting
+- Gap: need future RCT studies on CHWs employed by health plans (payers) or public health agencies
+
+Complementary evidence from IMPaCT (Penn Medicine):
+- RCT-based: every $1 invested returns $2.47 to Medicaid within the fiscal year
+- Reduced total hospital days by 65%
+- Doubled rate of patient satisfaction with primary care
+- Improved chronic disease control and mental health
+- Annual cost savings of $1.4 million for Medicaid enrollees after 12 months
+- First economic analysis of health system-based CHW intervention using RCT data
+
+## Agent Notes
+**Triage:** [CLAIM] — CHW programs have RCT-validated evidence of improved health outcomes AND positive ROI for Medicaid, making them the strongest evidence base for scalable non-clinical health interventions
+**Why this matters:** Frontier Gap 1 asks "what works to change the 80-90% non-clinical determinants?" CHWs are the strongest answer in the evidence base — 39 RCTs with consistent positive findings, plus the IMPaCT program showing $2.47 ROI per dollar invested in Medicaid
+**What surprised me:** The $2.47 ROI within the SAME fiscal year. Most prevention interventions have delayed returns. CHW programs generate savings fast enough to fit within annual budget cycles — this is what makes them scalable under current payment models.
+**KB connections:** [[medical care explains only 10-20 percent of health outcomes...]], [[SDOH interventions show strong ROI but adoption stalls...]], [[social isolation costs Medicare 7 billion annually...]]
+**Extraction hints:** Two claim candidates: (1) CHW programs are the most RCT-validated non-clinical health intervention with consistent evidence across 39 US trials, (2) IMPaCT's $2.47 Medicaid ROI within one fiscal year demonstrates that non-clinical health interventions can generate returns fast enough to fit within payer budget cycles
+
+## Curator Notes
+PRIMARY CONNECTION: SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action
+WHY ARCHIVED: Fills the most critical gap in Vida's KB — the evidence for what actually works to change non-clinical health determinants at scale. The 39 RCTs + IMPaCT ROI data provide the strongest evidence base for Belief 2's operational implications.

inbox/archive/2025-01-01-nashp-chw-state-policies-2024-2025.md

@@ -0,0 +1,50 @@
+---
+type: source
+title: "State Community Health Worker Policies: 2024-2025 Trends — Medicaid Reimbursement Expanding but Scaling Infrastructure Lags"
+author: "National Academy for State Health Policy (NASHP)"
+url: https://nashp.org/state-community-health-worker-policies-2024-2025-policy-trends/
+date: 2025-01-01
+domain: health
+secondary_domains: []
+format: report
+status: unprocessed
+priority: high
+triage_tag: entity
+tags: [community-health-workers, Medicaid, state-policy, reimbursement, scaling, SDOH]
+---
+
+## Content
+
+NASHP policy landscape report on CHW Medicaid reimbursement and certification trends across US states, 2024-2025.
+
+Key findings:
+- 20 states have received CMS-approved State Plan Amendments (SPAs) for CHW reimbursement since Minnesota's 2008 approval
+- 4 new SPAs approved in this period: Colorado, Georgia, Oklahoma, Washington
+- 15 states have approved Section 1115 demonstration waivers supporting CHW services
+- 7 states have established dedicated state offices for CHWs (Kansas, Kentucky, Massachusetts, Mississippi, New Mexico, Oklahoma, Texas)
+- 6 states enacted new CHW reimbursement legislation: Arkansas, Connecticut, Illinois, Mississippi, New Hampshire, North Dakota
+
+Billing infrastructure:
+- SPAs typically use fee-for-service reimbursement through 9896x CPT billing codes (health education focus)
+- Innovation: California, Minnesota, Washington adopting Medicare CHI and PIN "G codes"
+- Billing code uptake has been slow in many states — entities providing CHW services often cannot bill
+
+Scaling barriers:
+- Transportation is largest overhead expense; Medicaid does not cover provider travel
+- Community-based organizations (CBOs) lack infrastructure to contract with healthcare entities
+- "Community care hubs" emerging to coordinate administrative functions across CBO networks
+- COVID-19 funding streams ending, creating funding gaps
+- Sustainability requires braiding/blending funds from public health, health care, and social services
+
+Key trend: 7 of 10 most recent Section 1115 waivers focus on pre-release services for incarcerated individuals, recognizing lived experience as a CHW qualification.
+
+## Agent Notes
+**Triage:** [ENTITY] — tracks the CHW policy/reimbursement infrastructure across states, critical for understanding why CHW programs with strong evidence (39 RCTs, $2.47 ROI) still haven't scaled
+**Why this matters:** The evidence-to-implementation gap is the core mystery of Frontier Gap 1. CHW programs work in RCTs but only 20 states can reimburse them. The billing infrastructure is the bottleneck — identical to the VBC payment boundary problem.
+**What surprised me:** Only 20 states have SPAs after 17 years since Minnesota's 2008 approval. The CHW scaling failure parallels the VBC stall — the intervention works but the payment infrastructure doesn't support it. This is the SDOH version of "value-based care transitions stall at the payment boundary."
+**KB connections:** [[SDOH interventions show strong ROI but adoption stalls...]], [[value-based care transitions stall at the payment boundary...]]
+**Extraction hints:** Claim candidate: "Community health worker programs stall at the reimbursement boundary — only 20 states have Medicaid SPAs despite 17 years of evidence and $2.47 ROI, mirroring the VBC payment transition gap"
+
+## Curator Notes
+PRIMARY CONNECTION: SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action
+WHY ARCHIVED: Provides the structural/policy explanation for why evidence-backed CHW programs haven't scaled, directly extending the existing SDOH claim with specific infrastructure data

inbox/archive/2025-04-07-tufts-health-affairs-medically-tailored-meals-50-states.md

@@ -0,0 +1,60 @@
+---
+type: source
+title: "Medically Tailored Meals Could Prevent 10.8M Hospitalizations and Save $111B Over 5 Years — But RCTs Show No Glycemic Benefit"
+author: "Shuyue (Amy) Deng, Dariush Mozaffarian et al. (Tufts Food is Medicine Institute)"
+url: https://www.healthaffairs.org/doi/10.1377/hlthaff.2024.01307
+date: 2025-04-07
+domain: health
+secondary_domains: []
+format: paper
+status: unprocessed
+priority: high
+triage_tag: claim
+tags: [food-as-medicine, medically-tailored-meals, cost-effectiveness, SDOH, behavioral-health-infrastructure]
+---
+
+## Content
+
+Population-based open-cohort simulation model estimating state-specific changes in hospitalizations, healthcare spending, and cost-effectiveness of medically tailored meals (MTMs) for patients with diet-related diseases and limitations in activities of daily living.
+
+Simulation findings (Health Affairs, April 2025):
+- 5 years of MTM intervention: 10,792,000 hospitalizations prevented, $111.1 billion net savings nationally (2024 dollars, 3% discounting)
+- First-year savings: ~$23 billion
+- Hospitalizations prevented: 2.6+ million annually
+- Eligible population: 14+ million Americans
+- Net cost saving in 49 of 50 states (Alabama cost-neutral)
+- Largest per-patient savings: Connecticut $6,299, Pennsylvania $4,450, Massachusetts $4,331
+- Eligible population: average $30,900 annual healthcare expenditure, 0.53 hospitalizations/year
+- ~90% covered by Medicare/Medicaid
+- Most efficient: Maryland (2.3 patients per hospitalization prevented)
+- Mean program expense per meal: $11.15 (Food is Medicine Coalition 2024 survey)
+
+CRITICAL COUNTER-EVIDENCE — RCTs show weaker results:
+
+JAMA Internal Medicine 2024 RCT (intensive food-as-medicine for diabetes + food insecurity):
+- Intervention: up to 10 healthy meals/week + diabetes education + nurse evaluations + health coaching for 1 year
+- Result: HbA1c reduction NOT significantly different between treatment and control groups (adjusted difference: -0.10, 95% CI -0.46 to 0.25, P=.57)
+- No significant differences in blood pressure, hospitalization, ED use, outpatient visits, or total claims
+
+AHA Scientific Statement (Circulation, 2025) — systematic review of 14 US RCTs:
+- Food Is Medicine programs "often positively influence diet quality and food security"
+- BUT "impact on clinical outcomes was inconsistent and often failed to reach statistical significance"
+- More than one-third were early-stage smaller-scale trials
+- Called for "larger, higher-quality Food Is Medicine studies focusing on clinical outcomes"
+
+Geisinger Fresh Food Farmacy (pilot, n=37):
+- HbA1c dropped from 9.6 to 7.5 (2.1 points) — far greater than 0.5-1.2 from adding medication
+- Healthcare costs dropped 80% ($240K to $48K PMPY)
+- 27% lower ER usage, 70% lower hospital readmission
+- BUT: pilot study, n=37, not RCT, self-selected participants
+
+## Agent Notes
+**Triage:** [CLAIM] — The food-as-medicine evidence reveals a critical gap between simulation models projecting massive savings and RCTs showing null clinical results — this is the most important methodological tension in the behavioral health infrastructure evidence
+**Why this matters:** This source captures the central epistemological problem in non-clinical health interventions: simulation models use observational associations to project huge savings, but RCTs testing the actual intervention show no significant clinical benefit. The gap between "food insecurity predicts bad outcomes" (true) and "providing food improves outcomes" (unproven at RCT level) is a causal inference failure.
+**What surprised me:** The JAMA RCT null result is devastating. An intensive program (10 meals/week + education + coaching for a year) produced no significant difference in glycemic control. If this intensive intervention doesn't work in an RCT, the $111B simulation projections are built on observational associations that may not reflect causal mechanisms. The Geisinger results are striking but n=37 and uncontrolled.
+**KB connections:** [[medical care explains only 10-20 percent of health outcomes...]], [[SDOH interventions show strong ROI but adoption stalls...]]
+**Extraction hints:** Claim candidate: "Food-as-medicine simulation models project $111B in savings but RCTs consistently fail to show significant clinical outcomes, exposing a causal inference gap between observational association (food insecurity predicts disease) and intervention efficacy (providing food improves health)"
+
+## Curator Notes
+PRIMARY CONNECTION: SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action
+WHY ARCHIVED: The simulation-vs-RCT tension is the most important finding of this session. It challenges the assumption that addressing social determinants automatically improves health — the causal pathway may be more complex than "fix the determinant, fix the outcome."

inbox/archive/2025-09-01-lancet-public-health-social-prescribing-england-national-rollout.md

@@ -0,0 +1,55 @@
+---
+type: source
+title: "England's National Social Prescribing Rollout: 1.3M Referrals in 2023, Exceeding NHS Targets by 52% — But Robust Outcomes Evidence Still Missing"
+author: "UCL researchers (Lancet Public Health)"
+url: https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(25)00217-8/fulltext
+date: 2025-09-01
+domain: health
+secondary_domains: []
+format: paper
+status: unprocessed
+priority: high
+triage_tag: claim
+tags: [social-prescribing, UK, NHS, link-workers, non-clinical-interventions, international-health-systems, SDOH]
+---
+
+## Content
+
+Nationwide longitudinal observational study using Clinical Practice Research Datalink records from 1.2 million patients across 1,736 GP practices in England, tracking social prescribing trends 2019-2023.
+
+Scale findings:
+- 9.4 million GP consultations involved social prescribing codes (2019-2023)
+- 5.5 million consultations led to social prescribing referrals
+- 1.3 million patients referred in 2023 alone — exceeding original NHS 5-year target of 900,000 by 27-52%
+- Over 3,300 link workers now employed across England
+- Service refusal declined from 22% to 12% (2019-2023)
+
+Equity impacts:
+- 60% of patients offered social prescribing were female
+- 23% from ethnic minority groups
+- Representation from deprived areas increased from 23% to 42% (2017-2023)
+- BUT: rollout has NOT been sufficiently targeted at areas with highest need
+
+Healthcare utilization (from separate research):
+- 28% average reduction in GP service demand post-referral (range: 2-70%)
+- 24% average reduction in A&E attendance (range: 8-27%)
+- However: one study found GP workload overall was NOT reduced despite patient-level improvements
+
+Economic evidence (Frontiers 2026 systematic review, 18 studies):
+- SROI ratios: £1.17 to £7.08 per £1 invested
+- ROI estimates: only 0.11 to 0.43 per £1 invested (much lower)
+- "Robust economic evidence on social prescribing remains limited"
+- Standard health economic methods are "rarely applied"
+- 15 of 17 studies were uncontrolled before-and-after designs
+- Mean attrition rate: 38%
+
+## Agent Notes
+**Triage:** [CLAIM] — Social prescribing at national scale is the world's largest experiment in non-clinical health intervention, but the evidence quality is strikingly weak relative to the scale of implementation
+**Why this matters:** The UK social prescribing experiment is the most important international test of whether non-clinical interventions work at population scale. The scale is extraordinary (1.3M referrals/year, 3,300 link workers). But the evidence base is surprisingly weak: mostly uncontrolled studies, 38% attrition, no standardized outcome measures.
+**What surprised me:** The DISCONNECT between scale and evidence quality. England has implemented social prescribing for 1.3M patients/year but doesn't know if it works. This is the inverse of the CHW problem (strong evidence, low implementation). Social prescribing has massive implementation but weak evidence.
+**KB connections:** [[medical care explains only 10-20 percent of health outcomes...]], [[SDOH interventions show strong ROI but adoption stalls...]], [[social isolation costs Medicare 7 billion annually...]]
+**Extraction hints:** Two claim candidates: (1) "England's social prescribing program is the world's largest non-clinical health intervention reaching 1.3M patients annually but lacks the controlled evidence to validate its impact"; (2) "Social prescribing and CHW programs represent inverse failure modes — social prescribing scaled without evidence while CHW programs proved effectiveness without scaling"
+
+## Curator Notes
+PRIMARY CONNECTION: medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
+WHY ARCHIVED: First international health system evidence for Vida's KB (addresses Frontier Gap 2). The scale-vs-evidence tension challenges the assumption that non-clinical interventions just need more funding — they may also need better measurement.

inbox/archive/2026-01-01-frontiers-social-prescribing-health-economics-systematic-review.md

@@ -0,0 +1,53 @@
+---
+type: source
+title: "Health Economics of Social Prescribing: Systematic Review Finds Positive SROI but 'Robust Economic Evidence Remains Limited'"
+author: "Various (Frontiers in Public Health)"
+url: https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2026.1753435/full
+date: 2026-01-01
+domain: health
+secondary_domains: []
+format: paper
+status: unprocessed
+priority: medium
+triage_tag: claim
+tags: [social-prescribing, health-economics, cost-effectiveness, evidence-quality, international-health-systems]
+---
+
+## Content
+
+Systematic review of health economics evidence on social prescribing. 18 studies met inclusion criteria: 5 RCTs, 1 quasi-experimental, 12 mixed-methods. Searched seven databases plus gray literature.
+
+Geographic coverage: England, Wales, Ireland, Europe, Australia, New Zealand, Canada, USA.
+
+Intervention types analyzed:
+- Exercise-based or loneliness-prevention (n=10)
+- Coaching programs (n=3)
+- Nature-based interventions (n=3)
+- Dance/movement-based (n=2)
+
+Economic findings:
+- Social Return on Investment (SROI): positive returns for mental health and loneliness interventions
+- SROI ratios: £1.17 to £7.08 per £1 invested
+- Financial ROI: only 0.11 to 0.43 per £1 invested (much lower than SROI)
+- Standard health economic methods (CEA, CUA, CBA) "rarely applied"
+
+Key conclusion: "Robust economic evidence on social prescribing remains limited. Despite the availability of established health economic methods and tools, these are rarely applied to social prescribing, limiting the usefulness of existing studies for healthcare planning and commissioning."
+
+Major limitations: absence of standardized outcome measures, inconsistent definitions across models, inadequate evaluation frameworks preventing cross-setting comparisons.
+
+Complementary evidence on healthcare utilization (from separate reviews):
+- 28% average reduction in GP demand (range: 2-70%)
+- 24% average reduction in A&E attendance (range: 8-27%)
+- BUT: 15 of 17 utilization studies were uncontrolled before-and-after designs
+- Mean attrition rate: 38%
+
+## Agent Notes
+**Triage:** [CLAIM] — Social prescribing's economic evidence is thin despite massive scale, with SROI consistently positive but financial ROI below 1.0 per £1 — suggesting social value exceeds healthcare cost savings
+**Why this matters:** The SROI vs. financial ROI gap is telling: social prescribing produces social value (wellbeing, connectedness, reduced isolation) that SROI captures but financial ROI doesn't. This means social prescribing may be worthwhile from a societal perspective but NOT cost-saving for healthcare payers — a critical distinction for scaling decisions.
+**What surprised me:** Financial ROI of 0.11-0.43 per £1. Social prescribing may actually COST money from a healthcare budget perspective, even as it improves wellbeing. This is the opposite of the CHW story ($2.47 ROI). The implication: not all non-clinical interventions are created equal for healthcare payer economics.
+**KB connections:** [[SDOH interventions show strong ROI but adoption stalls...]], [[social isolation costs Medicare 7 billion annually...]]
+**Extraction hints:** Claim candidate: "Social prescribing produces measurable social value (SROI £1.17-£7.08 per £1) but does not reliably produce healthcare cost savings (financial ROI 0.11-0.43 per £1), making its scaling dependent on who bears the cost and who captures the value"
+
+## Curator Notes
+PRIMARY CONNECTION: social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day making loneliness a clinical condition not a personal problem
+WHY ARCHIVED: Provides the economic evidence (or lack thereof) for social prescribing, the most scaled non-clinical health intervention globally. The SROI/financial ROI divergence is a key finding for understanding which behavioral health interventions can scale under healthcare payment models.